| abstract |
The present invention relates to compounds of the general formula (I) wherein R1 is-OR1~,-SR1~ or is a heterocycloalkyl group; R1~ is lower alkyl, lower alkyl substituted by halogen or is -(CH2)n-cycloalkyl; R2 is-S(O)2-lower alkyl, -S(O)2NH-lower alkyl, NO2 or CN; X1 is CR3 or N; X2 is CR3~ or N; R3/R3~ are independently from each other hydrogen, halogen, lower alkyl, CN, NO2,-S(O)2-phenyl, -S(O)2-lower alkyl, -S(O)2-pyridin-2, 3 or 4-yl, phenyl, optionnally substituted by one or two substituents selected from the group consisting of NO2 or halogen, or is lower alkyl substituted by halogen or is -C(O)-lower alkyl; n is 0, 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. It has been found that the compounds of general formula (I) are good inhibitors of the glycine transporter 1 (GlyT-1). They may be used in the treatment of schizophrenia. |